Helen Kim
Senior Managing Director @ Vida Ventures
Santa Monica, United States
Helen Kim is a Series A investor at Vida Ventures in Santa Monica focused on Biotechnology and Health Care. Helen S. Kim is based out of Santa Monica, California and is the Senior Managing Director of Vida Ventures. Helen previously worked at The Column Group as a partner. Helen S. Kim attended the University of Chicago. Helen S. Kim has received Women’s Leadership Awards in their career.
- Total investments:
- 8
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Helen Kim invests in
Stages Helen Kim invests in
Countries Helen Kim invests in
Investment Focus
Industry
- Biotechnology 4 (50%)
- Health Care 3 (38%)
- Medical 2 (25%)
- Biopharma 2 (25%)
- Therapeutics 2 (25%)
Stage
- Series A 4 (50%)
- Series B 2 (25%)
- Series C 1 (13%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Poplar Therapeutics
|
Poplar Therapeutics anti-IgE therapy treats atopic diseases such as food allergy, allergic asthma, and atopic dermatitis. | $50M / Series A / Jan 07, 2026 | |
Protego Biopharma
|
Protego Biopharma develops therapeutics based on the clear human genetic link, excellent human safety profile, proof-of-principle efficacy. The company was founded in 2011 and is headquartered in San Diego, California. | $130M / Series B / Dec 01, 2025 | |
ReCode Therapeutics
|
ReCode Therapeutics is a development-stage biopharmaceutical company focused on the correction of the nonsense mutations that account for 1/3 of all inherited diseases, including approximately 10% of cystic fibrosis. They have combined selected tRNAs with their unique and diverse proprietary delivery platforms to create and developfirst-in-class suppressor tRNA-nanoparticle therapeutics for correcting nonsense mutations.ReCode’s diverse pipeline includes lead programs for primary ciliary dyskinesia (PCD) and nonsense mutations in cystic fibrosis (CF). The company’s proprietary non-viral lipid nanoparticle platform enables the delivery of a variety of payloads, and precise organ targeting of nucleic acid and protein payloads via both systemic and local delivery. ReCode is leveraging its nanoparticle and nucleic acid technologies across multiple modalities, including mRNA-mediated protein replacement therapies, first-in-class tRNA NanoCorrectors for diseases caused by nonsense mutations, and gene editing.The company was founded in 2015 and is based in Dallas, Texas. | $50M / Series B / Sep 19, 2023 | |
|
ReCode Therapeutics
|
ReCode Therapeutics is a development-stage biopharmaceutical company focused on the correction of the nonsense mutations that account for 1/3 of all inherited diseases, including approximately 10% of cystic fibrosis. They have combined selected tRNAs with their unique and diverse proprietary delivery platforms to create and developfirst-in-class suppressor tRNA-nanoparticle therapeutics for correcting nonsense mutations.ReCode’s diverse pipeline includes lead programs for primary ciliary dyskinesia (PCD) and nonsense mutations in cystic fibrosis (CF). The company’s proprietary non-viral lipid nanoparticle platform enables the delivery of a variety of payloads, and precise organ targeting of nucleic acid and protein payloads via both systemic and local delivery. ReCode is leveraging its nanoparticle and nucleic acid technologies across multiple modalities, including mRNA-mediated protein replacement therapies, first-in-class tRNA NanoCorrectors for diseases caused by nonsense mutations, and gene editing.The company was founded in 2015 and is based in Dallas, Texas. | $80M / Series B / Oct 21, 2021 | |
|
Protego Biopharma
|
Protego Biopharma develops therapeutics based on the clear human genetic link, excellent human safety profile, proof-of-principle efficacy. The company was founded in 2011 and is headquartered in San Diego, California. | $51M / Series A / Oct 19, 2021 | |
IconOVir Bio
|
IconOVir Bio is a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus therapy to improve the treatment of patients with cancer. | $77M / Series A / Jan 05, 2021 | |
|
ReCode Therapeutics
|
ReCode Therapeutics is a development-stage biopharmaceutical company focused on the correction of the nonsense mutations that account for 1/3 of all inherited diseases, including approximately 10% of cystic fibrosis. They have combined selected tRNAs with their unique and diverse proprietary delivery platforms to create and developfirst-in-class suppressor tRNA-nanoparticle therapeutics for correcting nonsense mutations.ReCode’s diverse pipeline includes lead programs for primary ciliary dyskinesia (PCD) and nonsense mutations in cystic fibrosis (CF). The company’s proprietary non-viral lipid nanoparticle platform enables the delivery of a variety of payloads, and precise organ targeting of nucleic acid and protein payloads via both systemic and local delivery. ReCode is leveraging its nanoparticle and nucleic acid technologies across multiple modalities, including mRNA-mediated protein replacement therapies, first-in-class tRNA NanoCorrectors for diseases caused by nonsense mutations, and gene editing.The company was founded in 2015 and is based in Dallas, Texas. | $80M / Series A / Mar 26, 2020 | |
PACT Pharma
|
Pact Pharma is a developer of personalized adoptive T cell therapies designed for the eradication of solid tumors.The company's therapies help in the identification of neo-epitopes that serve as private mutations for each patient's cancer as well as creates an opportunity to engineer autologous T cells that target and kill tumorsexpressing these neo-antigens, enabling physicians to recognize and remove each patient's cancer cells. | $75M / Series C / Jan 11, 2020 |
Co-Investors
About Vida Ventures
Vida Ventures’ mission is to bring science to life by advancing transformative biomedical innovations that have the potential to make a meaningful impact on the lives of patients. They want to do well by doing good for others. Vida Ventures is a bicoastal life sciences company building and investment firm, founded in 2017 by a group of scientists,physicians, entrepreneurs, and investors who are passionate about building and funding breakthroughs in biomedicine .
Vida Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Fred Cohen
Co-Founder & Sr. Managing Director
|
|||
|
Helen Kim
Senior Managing Director
|
|||
Mark Springel
Associate
|
|||
Arie Belldegrun
Co-Founder & Senior Managing Director; Founding Partner
|
|||
Arjun Goyal
Co-Founder and Managing Director
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Helen Kim invest in?
Helen Kim invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Series B stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Helen Kim last invest?
The most recent investment recorded for Helen Kim closed in Jan 2026. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
